Legend Biotech Director Tomas Heyman Receives 20,986 RSUs

What Happened Tomas J. Heyman, a director of Legend Biotech Corp (LEGN), received an award of 20,986 restricted share units (RSUs) on September 24, 2026. The acquisition price reported is $0.00 (an award/grant), so no cash was paid. Each RSU is a contingent right to receive one ordinary share upon settlement.

Key Details

• Transaction date and code: 2026-09-24, code A (award/grant). Report filed 2026-09-28 (timely).
• Shares/units awarded: 20,986 RSUs; reported acquisition price: $0.00.
• Shares owned after transaction: not disclosed in the filing.
• Vesting/settlement (footnote): 1/3 of the RSUs vest on December 20, 2027; the remainder vests in 12 equal quarterly installments beginning March 20, 2028, subject to continued service. Each RSU represents a contingent right to one ordinary share upon settlement.
• ADS note (footnote): The issuer’s ordinary shares may be represented by American Depositary Shares (ADSs); each ADS represents two ordinary shares.

Context This was an equity award (not a market purchase or sale). Awards are common for company insiders and reflect compensation/retention rather than an immediate buy or sell signal. Because these RSUs vest over time and require continued service, they are intended to align the director’s interest with long-term shareholder value rather than indicate near-term trading intent.